An update from Cardiff Oncology ( (CRDF) ) is now available.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Cardiff Oncology has reported promising initial results from its Phase 2 trial (CRDF-004) testing onvansertib with standard care in first-line RAS-mutated metastatic colorectal cancer. The data suggests enhanced efficacy with onvansertib, showing higher overall response rates compared to standard treatments alone. This development could represent a significant breakthrough for investors watching the oncology sector, though risks and uncertainties remain as the trials progress.
Learn more about CRDF stock on TipRanks’ Stock Analysis page.
